XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

6 clinical trials · Sponsor

Record	Firm	Date
Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial (NCT06974968)	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	2028-05-25
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P). (NCT07617012)	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	2026-06-15
Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease (NCT07166757)	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	2025-09-22
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis (NCT07118319)	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	2025-09-15
The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease (NCT07080775)	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	2025-08-05
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial (NCT06976229)	XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.	2025-07-02

Every clearance here is in the API, with alerts when new ones post.